{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:13:50Z","timestamp":1788297230642,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartrhythmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.hrthm.2026.07.038","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:24:06Z","timestamp":1785770646000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Atrial fibrillation in transthyretin amyloid cardiomyopathy: Mechanisms, prognostic implications, and management"],"prefix":"10.1016","author":[{"given":"Aaryamaan","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kushal","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Fazal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Joseph","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Bouzid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gracia","family":"Fahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos C.","family":"Siontis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco V.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy M.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0476-2972","authenticated-orcid":false,"given":"Tina","family":"Baykaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2026.07.038_bib1","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib2","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib3","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2026.07.038_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role","volume":"22","author":"Longhi","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.hrthm.2026.07.038_bib5","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.hrthm.2026.07.038_bib7","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.07.038_bib8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaccao.2024.02.007","article-title":"Effect of tafamidis on renal function in patients with transthyretin amyloid cardiomyopathy in ATTR-ACT","volume":"6","author":"Sperry","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.hrthm.2026.07.038_bib10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jaccao.2024.03.007","article-title":"Atrial fibrillation as a prognostic factor for all-cause mortality in patients with transthyretin amyloid cardiomyopathy","volume":"6","author":"Witteles","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib11","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1161\/CIRCULATIONAHA.112.113233","article-title":"Diastolic dysfunction and risk of atrial fibrillation: a mechanistic appraisal","volume":"126","author":"Rosenberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.07.038_bib12","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/01.CIR.0000034511.06350.DF","article-title":"Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation","volume":"106","author":"R\u00f6cken","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.07.038_bib13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacc.2016.10.059","article-title":"Cardiac autonomic dysfunction and incidence of atrial fibrillation: results from 20 years follow-up","volume":"69","author":"Agarwal","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/anec.12749","article-title":"Autonomic dysfunction in cardiac amyloidosis assessed by heart rate variability and heart rate turbulence","volume":"25","author":"Yamada","year":"2020","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib15","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hrthm.2026.07.038_bib16","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ejhf.2974","article-title":"Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms","volume":"25","author":"Elliott","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hrthm.2026.07.038_bib17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cardfail.2024.06.003","article-title":"Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"31","author":"Garcia-Pavia","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.hrthm.2026.07.038_bib18","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/eurheartj\/ehae923","article-title":"Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study","volume":"46","author":"Debonnaire","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2026.07.038_bib19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jaccao.2024.12.005","article-title":"A multicenter study of contemporary long-term tafamidis outcomes in transthyretin amyloid cardiomyopathy","volume":"7","author":"Masri","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101511","article-title":"Effect of tafamidis on clinical and functional parameters in transthyretin amyloid cardiomyopathy","volume":"4","author":"Kao","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.hrthm.2026.07.038_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.07.038_bib22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","article-title":"Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial","volume":"151","author":"Judge","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.07.038_bib23","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jacep.2022.11.005","article-title":"Tafamidis and incidence of atrial fibrillation in transthyretin amyloid cardiomyopathy","volume":"9","author":"Girvin","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib24","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jacep.2026.02.014","article-title":"Associations of tafamidis with new atrial fibrillation risk in transthyretin cardiomyopathy","volume":"12","author":"Zeis","year":"2026","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib25","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.hrthm.2024.01.056","article-title":"Atrial electrofunctional predictors of incident atrial fibrillation in cardiac amyloidosis","volume":"21","author":"Sinigiani","year":"2024","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.07.038_bib26","article-title":"Association between atrial uptake on cardiac scintigraphy with technetium-99m-pyrophosphate labeled bone-seeking tracers and atrial fibrillation","volume":"15","author":"Hussain","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.hrthm.2026.07.038_bib27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","article-title":"Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy","volume":"13","author":"Barbhaiya","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.07.038_bib28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/13506129.2018.1430027","article-title":"Reduced left atrial myocardial deformation irrespective of cavity size: a potential cause for atrial arrhythmia in hereditary transthyretin amyloidosis","volume":"25","author":"Henein","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.hrthm.2026.07.038_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13609","article-title":"Decreased left atrial appendage emptying velocity as a link between atrial fibrillation type, heart failure and older age and the risk of left atrial thrombus in atrial fibrillation","volume":"74","author":"Gawa\u0142ko","year":"2020","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.hrthm.2026.07.038_bib30","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jacc.2017.07.758","article-title":"Left atrial fibrosis and risk of cerebrovascular and cardiovascular events in patients with atrial fibrillation","volume":"70","author":"King","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib31","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/jce.12199","article-title":"Association of atrial fibrosis quantified using LGE-MRI with atrial appendage thrombus and spontaneous contrast on transesophageal echocardiography in patients with atrial fibrillation","volume":"24","author":"Akoum","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib32","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/j.jtha.2024.05.018","article-title":"Thromboembolic and bleeding risk in cardiac amyloidosis","volume":"22","author":"Tana","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.hrthm.2026.07.038_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2025.12.033","article-title":"Atrial mechanical contraction predicts cerebrovascular risk in patients with transthyretin amyloid cardiomyopathy and sinus rhythm","author":"Porcari","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib34","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.jacep.2023.03.013","article-title":"Left atrial strain may predict thrombus formation in patients with transthyretin cardiac amyloidosis","volume":"9","author":"Donnellan","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib35","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jacep.2023.11.015","article-title":"Prevalence and treatment of atrial fibrillation and flutter in cardiac amyloidosis","volume":"10","author":"Haslett","year":"2024","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib36","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ejhf.2566","article-title":"Systemic embolism in amyloid transthyretin cardiomyopathy","volume":"24","author":"Vilches","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hrthm.2026.07.038_bib37","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jacc.2020.10.057","article-title":"Persistence of left atrial appendage thrombus in patients with cardiac amyloidosis","volume":"77","author":"El-Am","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib38","article-title":"Left atrial appendage thrombi despite oral anticoagulation in transthyretin amyloid cardiomyopathy patients undergoing electrical cardioversion for atrial fibrillation or - flutter","volume":"61","author":"Poledniczek","year":"2025","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.hrthm.2026.07.038_bib39","doi-asserted-by":"crossref","first-page":"e1230","DOI":"10.1016\/j.hrthm.2025.03.1988","article-title":"Direct oral anticoagulants vs warfarin for atrial fibrillation in patients with transthyretin cardiac amyloidosis: a retrospective cohort analysis","volume":"22","author":"Habib","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.07.038_bib40","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2020.1810010","article-title":"Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding","volume":"28","author":"Mitrani","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.hrthm.2026.07.038_bib41","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1161\/CIRCULATIONAHA.120.052136","article-title":"Prevalence of atrial fibrillation and thromboembolic risk in wild-type transthyretin amyloid cardiomyopathy","volume":"143","author":"Bukhari","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.07.038_bib42","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/jce.70234","article-title":"Safety and efficacy of left atrial appendage occlusion in cardiac amyloidosis: A single-center retrospective study","volume":"37","author":"Mohamed","year":"2026","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib43","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jacep.2025.12.019","article-title":"Outcomes of left atrial appendage occlusion in patients with hypertrophic cardiomyopathy, rheumatic heart disease, and cardiac amyloidosis","volume":"12","author":"Alabdaljabar","year":"2026","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.amjcard.2021.07.028","article-title":"Management strategies for atrial fibrillation and flutter in patients with transthyretin cardiac amyloidosis","volume":"157","author":"Dale","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib45","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/jce.13046","article-title":"Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis","volume":"27","author":"Tan","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib46","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/pace.13992","article-title":"Catheter ablation of atrial fibrillation in cardiac amyloidosis","volume":"43","author":"Black-Maier","year":"2020","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib47","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/europace\/euz314","article-title":"Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis","volume":"22","author":"Donnellan","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.hrthm.2026.07.038_bib48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijcard.2022.04.045","article-title":"Routine ambulatory heart rhythm monitoring for detection of atrial arrhythmias in transthyretin cardiac amyloidosis","volume":"358","author":"Dale","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib49","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029339","article-title":"Safety of catheter ablation therapy for atrial fibrillation in cardiac amyloidosis","volume":"12","author":"Alhassan","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hrthm.2026.07.038_bib50","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1253\/circrep.CR-23-0022","article-title":"Prevalence and treatment of arrhythmias in patients with transthyretin and light-chain cardiac amyloidosis","volume":"5","author":"Miyamoto","year":"2023","journal-title":"Circ Rep"},{"key":"10.1016\/j.hrthm.2026.07.038_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead026","article-title":"Adverse outcomes of atrial fibrillation ablation in heart failure patients with and without cardiac amyloidosis: a Nationwide Readmissions Database analysis (2015\u20132019)","volume":"3","author":"Ullah","year":"2023","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.hrthm.2026.07.038_bib52","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euae155","article-title":"Clinical outcomes of catheter ablation for atrial fibrillation, atrial flutter, and atrial tachycardia in wild-type transthyretin amyloid cardiomyopathy: a proposed treatment strategy for catheter ablation in each arrhythmia","volume":"26","author":"Kanazawa","year":"2024","journal-title":"Europace"},{"key":"10.1016\/j.hrthm.2026.07.038_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0301753","article-title":"Catheter ablation of atrial arrhythmias in cardiac amyloidosis: impact on heart failure and mortality","volume":"19","author":"Maury","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.hrthm.2026.07.038_bib54","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euaf100","article-title":"Catheter ablation of atrial fibrillation in patients with cardiac amyloidosis and sarcoidosis: procedural findings and outcomes","volume":"27","author":"Oraii","year":"2025","journal-title":"Europace"},{"key":"10.1016\/j.hrthm.2026.07.038_bib55","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/j.hrthm.2025.04.020","article-title":"Efficacy of sinus rhythm maintenance after catheter ablation for atrial fibrillation in patients with transthyretin amyloid cardiomyopathy","volume":"22","author":"Yakabe","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.07.038_bib56","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJMoa1210356","article-title":"Biventricular pacing for atrioventricular block and systolic dysfunction","volume":"368","author":"Curtis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.07.038_bib57","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017335","article-title":"Cardiac resynchronization therapy for transthyretin cardiac amyloidosis","volume":"9","author":"Donnellan","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hrthm.2026.07.038_bib58","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/jce.14180","article-title":"Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation, and mortality","volume":"30","author":"Donnellan","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib59","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1093\/eurheartj\/ehab569","article-title":"AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial","volume":"42","author":"Brignole","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2026.07.038_bib60","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jacc.2022.07.019","article-title":"Randomized trial of left bundle branch vs biventricular pacing for Cardiac Resynchronization Therapy","volume":"80","author":"Wang","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib61","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jamacardio.2026.0083","article-title":"Long-term outcomes of left bundle-branch pacing vs biventricular pacing in heart failure: the HeartSync-LBBP randomized clinical trial","volume":"11","author":"Chen","year":"2026","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib62","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jamacardio.2026.0101","article-title":"Conduction system vs biventricular pacing in heart failure: the PhysioSync-HF randomized clinical trial","volume":"11","author":"Zimerman","year":"2026","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib63","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib64","doi-asserted-by":"crossref","DOI":"10.31083\/RCM39760","article-title":"Prognostic factors and implantable cardioverter-defibrillator outcomes in transthyretin cardiac amyloidosis: a comprehensive retrospective study","volume":"27","author":"Raslan","year":"2026","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.hrthm.2026.07.038_bib65","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.07.038_bib66","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2026.07.038_bib67","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology solution set oversight committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.07.038_bib69","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jacc.2025.09.004","article-title":"Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC Concise Clinical Guidance","volume":"87","author":"Kittleson","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.07.038_bib70","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.amjcard.2025.06.015","article-title":"Atrial fibrillation burden, risk factors, and prognosis in wild-type transthyretin amyloidosis cardiomyopathy","volume":"254","author":"Skov","year":"2025","journal-title":"Am J Cardiol"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527126026500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527126026500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:20:26Z","timestamp":1788294026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527126026500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":70,"alternative-id":["S1547527126026500"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2026.07.038","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atrial fibrillation in transthyretin amyloid cardiomyopathy: Mechanisms, prognostic implications, and management","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2026.07.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Heart Rhythm Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}